AstraZeneca Shocker Reminds Investors Miracle Drugs Are No Remedy for Risk

Chasing exciting new developments in medicine can be a very expensive endeavor. Such is the takeaway from AstraZeneca’s announcement that a hotly anticipated clinical trial didn’t meet expectations.